Fmr LLC Buys 3,537 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Fmr LLC increased its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 236.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,032 shares of the company’s stock after purchasing an additional 3,537 shares during the quarter. Fmr LLC’s holdings in Tarsus Pharmaceuticals were worth $166,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TARS. Alpha DNA Investment Management LLC grew its holdings in Tarsus Pharmaceuticals by 9.1% during the 2nd quarter. Alpha DNA Investment Management LLC now owns 15,174 shares of the company’s stock valued at $412,000 after buying an additional 1,261 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Tarsus Pharmaceuticals by 33.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after acquiring an additional 1,530 shares in the last quarter. Profund Advisors LLC increased its holdings in Tarsus Pharmaceuticals by 26.8% during the 2nd quarter. Profund Advisors LLC now owns 9,126 shares of the company’s stock worth $248,000 after acquiring an additional 1,929 shares during the period. Quest Partners LLC purchased a new stake in Tarsus Pharmaceuticals in the 2nd quarter worth approximately $61,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Tarsus Pharmaceuticals by 64.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock valued at $241,000 after purchasing an additional 2,879 shares during the period. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Price Performance

TARS opened at $52.91 on Friday. The stock has a market capitalization of $2.02 billion, a P/E ratio of -13.89 and a beta of 1.04. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a 12-month low of $18.99 and a 12-month high of $56.77. The stock has a 50-day moving average price of $46.51 and a 200-day moving average price of $35.02.

Analyst Ratings Changes

Several research firms have recently weighed in on TARS. Oppenheimer upped their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. The Goldman Sachs Group upped their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. Finally, William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $54.20.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.